{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-015003","form_type":"8-K","ticker":"ELAB","cik":"0001840563","company_name":"PMGC Holdings Inc.","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.487983+00:00","generated_at":"2026-05-16T03:22:34.504364+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PMGC subsidiary NorthStrive signs exclusive license for EL-22/EL-32 in animal health","bullets":["Definitive license with Modulant Biosciences for myostatin-engineered probiotic EL-22 and EL-32.","Modulant gets exclusive, royalty-bearing, sublicensable license for non-human animal health worldwide except Korea.","Modulant pays value (undisclosed) and handles development, manufacturing, regulatory, commercialization.","License excludes human pharmaceutical applications; shared ownership of improvements.","Follows binding term sheet from May 2025; no assurance of commercial success."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-015003","json":"https://secwatch.observer/filing/0001213900-26-015003.json","markdown":"https://secwatch.observer/filing/0001213900-26-015003.md","text":"https://secwatch.observer/filing/0001213900-26-015003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026015003/0001213900-26-015003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026015003/ea0276475-8k_pmgc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:22:34.504364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}